| Bioactivity | Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) [1][2]. |
| Invitro | Nidanilimab (CAN04; 20 µg/mL; 小鼠 MC38 结肠癌细胞) 具有糖工程介导增强的抗体依赖性细胞毒性 (ADCC, EC50<1 nM)[2]。Nidanilimab (20 µg/mL; 小鼠 MC38 结肠癌细胞) 阻断 IL1α 和 IL1β 信号通路，IC50 值分别为 3.9 nM和 4.1 nM[2]。 |
| In Vivo | Nidanilimab (CAN04; 10 mg/kg; i.p.; 裸 C57Bl/6 小鼠) 增加了两种常用的铂基化疗药物顺铂 (HY-17394)/吉西他滨 (HY-17026) 和卡铂 (HY-17393)/吉西他滨 (HY-17026) 的疗效[1]。 Animal Model: |
| Name | Nidanilimab |
| CAS | 2171061-85-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Millrud CR, et, al. The anti-IL1RAP antibody CAN04 increases tumor sensitivity to platinum-based chemotherapy. [2]. Rydberg Millrud C, et, al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol Immunother. 2022 Aug 29. |